Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAT657)

• Drug Name: SDZ-62-826 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 1393
  TTD Drug ID: DMAT657

Molecule-Related Drug Atlas

Drug(s) Targeting GMCSFR-alpha (CSF2RA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sargramostim	DMY0M8J	Bone marrow transplantation	QB63.6	Approved	[3]
B-cell lymphoma vaccine	DMBRFUQ	Follicular lymphoma	2A80	Preregistration	[4]
Pixykine	DMCA6BW	Human immunodeficiency virus infection	1C62	Phase 3	[5]
Molgramostim	DM2TNJ1	Autoimmune pulmonary alveolar proteinosis	CB04.31	Phase 3	[6]
AFTVac	DMD3XMG	Glioblastoma multiforme	2A00.0	Phase 2	[7]
Mavrilimumab	DMMVFRC	Rheumatoid arthritis	FA20	Phase 2	[8]
GM-CSF cancer vaccine	DML6PO5	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Leukemia cancer vaccine	DMIFGLY	Acute myeloid leukaemia	2A60	Phase 2	[2]
Myeloma cancer vaccine	DMO1XUK	Multiple myeloma	2A83	Phase 2	[2]
MOR-103	DMXVIQN	Multiple sclerosis	8A40	Phase 1/2	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GMCSFR-alpha (CSF2RA)	TT6MP2Z	CSF2R_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004355)
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707).
• [3] Stem cell transplantation and hematopoietic growth factors. Curr Hematol Rep. 2002 Nov;1(2):103-9.
• [4] Idiotypevaccinetherapy (BiovaxID) infollicularlymphomain first complete remission: Phase III clinical trial results, Journal of Clinical Oncology, Vol 27, No 18S (June 20 Supplement), 2009: 2.
• [5] Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired... Br J Haematol. 1998 Nov;103(2):304-7.
• [6] Clinical pipeline report, company report or official report of gensci-china.
• [7] Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9.
• [8] Clinical pipeline report, company report or official report of MedImmune (2011).
• [9] MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis. 2015 Jun;74(6):1058-64.